Attovia Therapeutics to Participate in Upcoming Investor Conferences
Attovia Therapeutics will meet investors and present at Citi and Morgan Stanley healthcare conferences in September 2026, with webcast access provided.
Rhea-AI Summary
Attovia Therapeutics (ATTO)/b) will participate in two investor conferences in September 2026.Management will hold 1x1 meetings at Citi’s 2026 Biopharma Back to School Conference on September 10, 2026. The company will also join a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, from 10:00 AM to 10:35 AM EST, with a live webcast and 90-day replay available via Attovia’s investor website.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:
Citi’s 2026 Biopharma Back to School Conference
Format: 1x1 meetings
Date: Thursday, September 10, 2026
Morgan Stanley 24th Annual Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 16, 2026
Time: 10:00 AM - 10:35 AM EST
The webcast of the Morgan Stanley fireside chat will be accessible on the investor section of Attovia’s website. A replay of the webcast will be available for approximately 90 days following the conference.
About Attovia Therapeutics, Inc.
Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY™ biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates.
Attovia’s lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.
Investor and Media Contact
Attovia Therapeutics
ir@attovia.com
PJ Kelleher
LifeSci Advisors LLC
617-430-7579
pkelleher@lifesciadvisors.com
FAQ
What investor conferences will Attovia Therapeutics (ATTO) attend in September 2026?
Attovia Therapeutics will participate in Citi’s 2026 Biopharma Back to School Conference and the Morgan Stanley 24th Annual Global Healthcare Conference in September 2026. The company plans 1x1 investor meetings and a webcast fireside chat during these events.
When is Attovia Therapeutics’ (ATTO) Citi 2026 Biopharma Back to School Conference participation?
Attovia Therapeutics management will participate in Citi’s 2026 Biopharma Back to School Conference on Thursday, September 10, 2026, in a 1x1 meeting format with investors.
When is Attovia Therapeutics’ (ATTO) Morgan Stanley 24th Annual Global Healthcare Conference fireside chat?
The Attovia Therapeutics fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference is scheduled for Wednesday, September 16, 2026, from 10:00 AM to 10:35 AM EST.
How can investors access the Attovia Therapeutics (ATTO) Morgan Stanley conference webcast?
The webcast of Attovia Therapeutics’ fireside chat at the Morgan Stanley conference will be accessible through the investor section of the company’s website, with a replay available for approximately 90 days after the event.